Home > Insider Trading > Filing (0001209191-14-007971)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1305253	Celladon Corp	CLDN	Biological Products, (No Disgnostic Substances) (2836)	330971591

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1591249	Joshua Funder	12760 High Bluff Drive, Ste 240 San Diego CA 92130		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-02-04	943,798	$0.00	943,798	No	4	C	Indirect	GBS Bioventures IV
Common Stock	Acquisiton	2014-02-04	23,145	$8.00	966,943	No	4	C	Indirect	GBS Bioventures IV
Common Stock	Acquisiton	2014-02-04	227,261	$8.00	1,194,204	No	4	P	Indirect	GBS Bioventures IV

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	GBS Bioventures IV
No	4	C	Indirect	GBS Bioventures IV
No	4	P	Indirect	GBS Bioventures IV

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-1 Convertible Preferred Stock	Disposition	2014-02-04	11,788,047	$0.00	943,798	$0.00
Common Stock	Convertible Promissory Notes	Disposition	2014-02-04	23,145	$8.00	23,145	$8.00
Series A-1 Preferred Stock	Series A-1 Preferred Warrants	Disposition	2014-02-04	672,060	$0.00	672,060	$0.45
Common Stock	Common Warrants	Acquisiton	2014-02-04	53,807	$0.00	53,807	$5.61

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect
0	2013-10-15	2018-10-15	No	4	C	Indirect
53,807	2013-10-15	2018-10-15	No	4	C	Indirect

Footnotes

Every 12.49 shares of Series A-1 Preferred Stock automatically converted into 1 share of Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
Shares held by GBS Bioventures IV. The Reporting Person shares voting and investment power with respect to the shares held by GBS Bioventures IV and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
Automatic conversion, in connection with the Issuer's initial public offering, of convertible promissory notes, including principal and accrued interest.
The shares were purchased at the Issuer's initial public offering.
Represents the automatic conversion of Series A-1 Preferred Warrants into Common Stock Warrants on a 1-for-12.49 basis upon the closing of the Issuer's initial public offering.